GGrantIndex
← Leaderboards

Priti Kumar

Yale University

$9,682,784
Attributed
$18,409,948
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.9M · FY200925
$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,409,948 · 12

By mechanism

R01$12,069,004 · 5
R24$1,728,398 · 1
R33$1,489,046 · 1
R21$1,371,281 · 3
T32$1,154,069 · 1
R56$598,150 · 1

Most similar at Yale University

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsIn VivoMouse ModelHumanized MouseViralHiv InfectionsViral ReservoirVirusAntiretroviral TherapyInfectionProvirusesViral ReboundMeasurementAcquired Immunodeficiency SyndromeCcr5 GeneDesignImmuneAntibodiesHiv-1GenerationsTargeted DeliveryBindingAutomobile DrivingLead

Grant awards (35)

Targeting the HIV-1 reservoir at cART initiation with CD4-mimetic interventions$1,363,055
R01 · FY2025 · AI · contact PI
Novel Humanized Mouse Models For Engraftment of Tissue-Specific Human Macrophage Population$846,948
R24 · FY2025 · OD
Capsid-engineered AAV vectors with Brec1-based gene therapeutics for inactivating the HIV reservoir$709,843
R01 · FY2025 · AI · contact PI
Targeting the HIV-1 reservoir at cART initiation with CD4-mimetic interventions$1,314,572
R01 · FY2024 · AI · contact PI
Novel Humanized Mouse Models For Engraftment of Tissue-Specific Human Macrophage Population$881,450
R24 · FY2024 · OD
Capsid-engineered AAV vectors with Brec1-based gene therapeutics for inactivating the HIV reservoir$769,737
R01 · FY2024 · AI · contact PI
T cell-targeted lentiviral vectors with Cas9/RNP for the in vivo gene therapy of HIV-AIDS$745,410
R01 · FY2024 · AI · contact PI
Predoctoral Training Program in Virology$187,646
T32 · FY2024 · AI · contact PI
T cell-targeted lentiviral vectors with Cas9/RNP for the in vivo gene therapy of HIV-AIDS$762,160
R01 · FY2023 · AI · contact PI
Predoctoral Training Program in Virology$212,313
T32 · FY2023 · AI · contact PI
Predoctoral Training Program in Virology$199,709
T32 · FY2022 · AI · contact PI
T cell-targeted lentiviral vectors with Cas9/RNP for the in vivo gene therapy of HIV-AIDS$753,785
R01 · FY2021 · AI · contact PI
Predoctoral Training Program in Virology$189,515
T32 · FY2021 · AI · contact PI
T cell-targeted lentiviral vectors with Cas9/RNP for the in vivo gene therapy of HIV-AIDS$725,111
R01 · FY2020 · AI · contact PI
Exploring antibody-Fc effector function in humanized mouse models of HIV latency$498,157
R33 · FY2020 · AI · contact PI
Exploiting Natural Post-Integration Barriers to Restrict HIV-1 Replication$203,222
R21 · FY2020 · AI
Predoctoral Training Program in Virology$182,332
T32 · FY2020 · AI · contact PI
T cell-targeted lentiviral vectors with Cas9/RNP for the in vivo gene therapy of HIV-AIDS$683,236
R01 · FY2019 · AI · contact PI
Exploring antibody-Fc effector function in humanized mouse models of HIV latency$493,003
R33 · FY2019 · AI · contact PI
Exploiting Natural Post-Integration Barriers to Restrict HIV-1 Replication$256,604
R21 · FY2019 · AI
Long-acting combination antiretroviral therapy for HIV-AIDS$598,150
R56 · FY2018 · AI · contact PI
Exploring antibody-Fc effector function in humanized mouse models of HIV latency$497,886
R33 · FY2018 · AI · contact PI
Predoctoral Training Program in Virology$182,554
T32 · FY2018 · AI · contact PI
In vivo genomic editing of hematopoietic cells for HIV resistance$607,873
R01 · FY2017 · AI · contact PI
Exploring antibody-Fc effector function in humanized mouse models of HIV latency$243,607
R21 · FY2017 · AI · contact PI
In vivo genomic editing of hematopoietic cells for HIV resistance$607,873
R01 · FY2016 · AI · contact PI
Exploring antibody-Fc effector function in humanized mouse models of HIV latency$220,871
R21 · FY2016 · AI · contact PI
In vivo genomic editing of hematopoietic cells for HIV resistance$607,873
R01 · FY2015 · AI · contact PI
In vivo genomic editing of hematopoietic cells for HIV resistance$250,000
R01 · FY2014 · AI · contact PI
Targeting HIV cell-to-cell transmission$554,946
R01 · FY2012 · AI
Versatile carriers for cell-specific siRNA delivery in vivo$207,552
R21 · FY2012 · AI · contact PI
Targeting HIV cell-to-cell transmission$548,012
R01 · FY2011 · AI
Versatile carriers for cell-specific siRNA delivery in vivo$239,425
R21 · FY2011 · AI · contact PI
Targeting HIV cell-to-cell transmission$529,040
R01 · FY2010 · AI
Targeting HIV cell-to-cell transmission$536,478
R01 · FY2009 · AI